VSIR and breast carcinoma: Analysis of the Tumor Immune Single Cell Hub (TISCH) database (Figure 7) supported these findings by demonstrating that VISTA was highly expressed on immune cells relative to stromal cells and that its expression was significantly more favorable than that of PD-1, PDL-1, and CTLA-4 in breast cancer.